Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232509 | 0.86 | CNR1 (0.38) | CNR1CNR2PTGER1L3MBTL1SMPD1 | |
| SCHEMBL3219891 | 0.85 | CNR1 (0.48) | CNR1CNR2GPR84SMPD1 | |
| SCHEMBL1234257 | 0.83 | PLA2G10 (0.40) | PTGER1L3MBTL1NQO2PLA2G10PIM1 | |
| SCHEMBL1232364 | 0.81 | CNR1 (0.39) | CNR1CNR2PTGER1L3MBTL1NR3C2 | |
| SCHEMBL1234011 | 0.77 | PTGER1 (0.38) | CNR1CNR2PTGER1L3MBTL1NR3C2 | |
| SCHEMBL5568334 | 0.77 | PTGER1 (0.46) | CNR1CNR2PTGER1L3MBTL1SMPD1 | |
| SCHEMBL1233659 | 0.76 | CNR1 (0.45) | CNR1CNR2L3MBTL1NR3C2PLA2G10 | |
| SCHEMBL1233850 | 0.76 | CYP4F2 (0.33) | CNR1CNR2PTGER1L3MBTL1PLA2G10 | |
| SCHEMBL1233324 | 0.76 | ALDH1A1 (0.41) | — | |
| SCHEMBL1233594 | 0.76 | CNR1 (0.44) | CNR1CNR2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9145410-B2 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2012-05-17 | — | — | US | disclosed |
| US-7879849-B2 | such as 1-(2-Methylpropyl)-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine, used as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-7544697-B2 | Pyrazolopyridines and analogs thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1696912-A4 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1863809-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107753-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1696912-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
| WO-2005079195-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | IL4, IL4I1, IL2 | CNR1 2505/4885CNR2 1476/4885PTGER1 1000/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | CNR1 2696/4885CNR2 1601/4885PTGER1 1076/4885 |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL4I1, IL2 | CNR1 2505/4885CNR2 1476/4885PTGER1 1000/4885 |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL2, IL4I1 | CNR1 2696/4885CNR2 1601/4885PTGER1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.